

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### Effects of oral glibenclamide on reduction of size of brain contusions and peri contusional edema and prognosis of patients with moderate and severe traumatic brain injury: a randomized clinical trial

#### Protocol summary

##### Summary

The aim of the current study is to determine effects of oral Glibenclamide in moderate and severe TBI and its role in reduction of size of contusions and pericontusional edema. For this purpose we will include 104 patients with moderate and severe traumatic brain injury (TBI) between 18 to 75 years within 10-hours of injury. Those undergoing surgical evacuation of the hematoma, spinal cord injury and coagulopathy would be excluded from the study. The patients would be assigned to two study groups to receive oral glibenclamide in a dosage of 10mg daily for 10 days or placebo. The Glasgow Outcome Scale (GOS) and GOSE and Disability Rating scale (DRS) would be assessed after 1, 3 and 6 months of injury. The brain contusion volume and edema would be measured on admission, 3rd day and 10th day after the intervention. Clinical scales and size of contusions and pericontusional edema will be compared in the two groups.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT2014121720353N1**  
Registration date: **2015-05-15, 1394/02/25**  
Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2015-05-15, 1394/02/25

##### Registrant information

###### Name

Nima Derakhshan

###### Name of organization / entity

Neurosurgery Department, Shiraz University of

Medical Sciences

###### Country

Iran (Islamic Republic of)

###### Phone

+98 71 3647 4259

###### Email address

derakhshn@sums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

Vice Chancellor of Research, Shiraz University of Medical Sciences

##### Expected recruitment start date

2015-04-01, 1394/01/12

##### Expected recruitment end date

2016-10-01, 1395/07/10

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Effects of oral glibenclamide on reduction of size of brain contusions and peri contusional edema and prognosis of patients with moderate and severe traumatic brain injury: a randomized clinical trial

##### Public title

Effects of oral glibenclamide in patients with traumatic brain injury

##### Purpose

Treatment

##### Inclusion/Exclusion criteria

Inclusion criteria: Documented closed head injury; Age between 18 and 75 years; Having brain contusions on initial brain CT scan; Taking the first dosage of

medication within first 10 hours of trauma event;  
GCS:5-13 without influence of sedations upon admission;  
Obtaining written informed consent from legally authorized representative  
Exclusion criteria: Having a lesion on brain CT which urges a surgical evacuation at any time of hospital admission (Surgical EDH, SDH, ICH or midline shift>5mm and decompressive craniectomy); Spinal cord injury or spinal column instability with neurologic deficit; Penetrating brain injury; Any blood glucose under 50mg/dL or over 500mg/d; Severe renal disorder from past history or Cr>2.5 or patients on hemodialysis; Severe liver disease from past history or total bilirubin above 1.5 times of normal value; INR>1.6; Systolic BP below 90mmHg on admission without respond to fluid resuscitation; Pregnant women or a positive pregnancy test or those who intend to breastfeed during study days; Associated severe non-survivable injury; History of previous brain problems (Tumor, infections, strokes, ...); Usage of warfarin, heparin, clopidogrel, LMWH within 72 hours prior to traumatic event

**Age**

From **18 years** old to **75 years** old

**Gender**

Both

**Phase**

3

**Groups that have been masked**

*No information*

**Sample size**

Target sample size: **104**

**Randomization (investigator's opinion)**

Randomized

**Randomization description****Blinding (investigator's opinion)**

Double blinded

**Blinding description****Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Shiraz University of Medical Sciences

**Street address**

Zand Avenue

**City**

Shiraz

**Postal code****Approval date**

2015-01-25, 1393/11/05

**Ethics committee reference number**

93-0101-7757

**Health conditions studied****1****Description of health condition studied**

Brain contusion

**ICD-10 code**

S06.3

**ICD-10 code description**

Focal brain injury

**Primary outcomes****1****Description**

Brain contusion and precontusional edema volume

**Timepoint**

Onadmission, day 3 and 10 after intervention

**Method of measurement**

CT-volumetry of brain contusions

**2****Description**

Outcome

**Timepoint**

6 months after intervention

**Method of measurement**

Glasgow Outcome Scale (GOS)

**Secondary outcomes**

empty

**Intervention groups****1****Description**

Group 1: Oral glibenclamide 10 mg daily for 10 days

**Category**

Treatment - Drugs

**2****Description**

Group 2 : Placebo agent, 10mg Daily, for 10 days

**Category**

Treatment - Drugs

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Shahid Rajaei hospital

**Full name of responsible person**

Nima Derakhshan

**Street address**  
Chamran Avenue  
**City**  
Shiraz

## Sponsors / Funding sources

1

### Sponsor

**Name of organization / entity**  
Vice Chancellor of Research, Shiraz University of  
Medical Sciences

**Full name of responsible person**  
Seyed Masoum Masoumpoor

**Street address**  
Zand Avenue

**City**  
Shiraz

### Grant name

### Grant code / Reference number

### Is the source of funding the same sponsor organization/entity?

Yes

### Title of funding source

Vice Chancellor of Research, Shiraz University of Medical  
Sciences

### Proportion provided by this source

100

### Public or private sector

*empty*

### Domestic or foreign origin

*empty*

### Category of foreign source of funding

*empty*

### Country of origin

### Type of organization providing the funding

*empty*

## Person responsible for general inquiries

### Contact

**Name of organization / entity**  
Shiraz University of Medical Sciences

**Full name of responsible person**  
Nima Derakhshan

**Position**  
Resident of Neurosurgery

### Other areas of specialty/work

**Street address**  
Neurosurgery department office, Namzi hospital,  
Namazi square

**City**  
Shiraz

### Postal code

**Phone**  
+98 71 3647 4259

**Fax**  
+98 71 3647 4259

**Email**  
derakhshn@sums.ac.ir

**Web page address**

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**  
Shiraz University of Medical Sciences

**Full name of responsible person**  
Hosseinali Khalili

**Position**  
Assistant Professor

### Other areas of specialty/work

**Street address**  
Shahid Rajaei Hospital, Chamran Avenue,

**City**  
Shiraz

### Postal code

**Phone**  
+98 71 3636 4001

### Fax

**Email**  
khalilih16@gmail.com

**Web page address**

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Shiraz University of Medical Sciences

**Full name of responsible person**  
Nima Derakhshan

**Position**  
Resident of Neurosurgery

### Other areas of specialty/work

**Street address**  
Department of Neurosurgery Office, Namazi hospital,  
Namazi square

**City**  
Shiraz

### Postal code

**Phone**  
+98 71 3647 4259

### Fax

**Email**  
**Web page address**

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

*empty*

### Study Protocol

*empty*

### Statistical Analysis Plan

*empty*

### Informed Consent Form

*empty*

### Clinical Study Report

*empty*

### Analytic Code

*empty*

### Data Dictionary

*empty*